# Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00568880** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 25 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** bortezomib
- **DRUG:** hydroxychloroquine

## Key facts

- **NCT ID:** NCT00568880
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-08
- **Primary completion:** 2011-06-22
- **Final completion:** 2011-06-22
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568880, "Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00568880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*